Table 1.
Relationship between the expression of PD-L1 protein and clinicopathological features in TETs.
| Clinicopathological factors | Case number | PD-L1 expression | Positive rate (%) | χ 2 | P value | |
|---|---|---|---|---|---|---|
| + | − | |||||
| Gender | ||||||
| Male | 30 | 20 | 10 | 33.33 | 3.243 | 0.092 |
| Female | 40 | 18 | 22 | 45.00 | ||
| Age | ||||||
| ≤50 years | 16 | 7 | 9 | 43.75 | 0.928 | 0.399 |
| >50 years | 54 | 31 | 23 | 57.41 | ||
| Tumor size | ||||||
| ≤4 cm | 41 | 22 | 19 | 53.66 | 0.016 | 1.000 |
| >4 cm | 29 | 16 | 13 | 55.17 | ||
| Histological classification | ||||||
| Type A | 11 | 4 | 7 | 36.36 | 20.648 | 0.001∗ |
| Type AB | 13 | 2 | 11 | 15.39 | ||
| Type B1 | 9 | 3 | 6 | 33.33 | ||
| Type B2 | 7 | 6 | 1 | 85.71 | ||
| Type B3 | 10 | 9 | 1 | 90.00 | ||
| Type C thymic carcinoma | 20 | 14 | 6 | 70.00 | ||
| Masaoka-Koga staging | ||||||
| Stage I | 32 | 10 | 22 | 31.25 | 12.402 | 0.004∗ |
| Stage II | 4 | 3 | 1 | 75.00 | ||
| Stage III | 20 | 15 | 5 | 75.00 | ||
| Stage IV | 14 | 10 | 4 | 71.42 | ||
| With/without myasthenia gravis | ||||||
| Yes | 11 | 7 | 4 | 63.64 | 0.460 | 0.533 |
| No | 59 | 31 | 28 | 52.54 | ||
| Metastasis | ||||||
| Yes | 14 | 10 | 4 | 71.43 | 2.072 | 0.231 |
| No | 56 | 28 | 28 | 50.00 | ||
| Radiotherapy | ||||||
| Yes | 37 | 26 | 11 | 70.27 | 8.081 | 0.008∗ |
| No | 33 | 12 | 21 | 36.36 | ||
| Chemotherapy | ||||||
| Yes | 21 | 16 | 5 | 76.19 | 5.800 | 0.02∗ |
| No | 49 | 22 | 27 | 44.90 | ||
∗ P < 0.05.